Metalloproteinases as Targets for Anti-Inflammatory Drugs

  • Kevin M. K. Bottomley
  • David Bradshaw
  • John S. Nixon

Part of the Progress in Inflammation Research book series (PIR)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Jerauld S. Skotnicki, Jeremy I. Levin, Arie Zask, Loran M. Killar
    Pages 17-57
  3. Michael W. Lark, Ellen K. Bayne, L. Stefan Lohmander
    Pages 59-83
  4. Andrew J.H. Gearing, Sally E. Adams, John C. Clements, Karen M. Miller
    Pages 85-98
  5. Gillian Borland, Kyriakos M. Tanousis, Ann Ager
    Pages 163-186
  6. Marcia Moss, J. David Becherer, Marcos Milla, Gregory Pahel, Mill Lambert, Rob Andrews et al.
    Pages 187-203
  7. Back Matter
    Pages 205-207

About this book


This volume describes recent research in the field of metalloproteinases (a family of enzymes that can catalyze tissue degradation), in particular their participation in autoimmune diseases such as rheumatoid arthritis, reviewing the latest developments in metalloproteinase inhibitor design and the current status of clinical candidates. This volume is intended not only for those active in research into metalloproteinases but also for those with an interest in inflammatory diseases. Thus it addresses both academic and industrial researchers.


Arthritis autoimmune disease diseases metabolism protein research rheumatism rheumatoid arthritis tissue

Editors and affiliations

  • Kevin M. K. Bottomley
    • 1
  • David Bradshaw
    • 1
  • John S. Nixon
    • 1
  1. 1.Roche Discovery WelwynRoche Products Ltd.GB-HerfordshireUK

Bibliographic information

Industry Sectors
Health & Hospitals
Consumer Packaged Goods